Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 10:8:546.
doi: 10.3389/fcell.2020.00546. eCollection 2020.

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

Alexandre Perla  1   2 , Lívia Fratini  1   2 , Paula S Cardoso  1   2 , Carolina Nör  3   4 , André T Brunetto  1   5 , Algemir L Brunetto  1   5 , Caroline Brunetto de Farias  1   5 , Mariane Jaeger  1   5 , Rafael Roesler  1   2
Affiliations
Review

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

Alexandre Perla et al. Front Cell Dev Biol. .

Abstract

Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.

Keywords: brain tumor; ependymoma; epigenetics; glioma; histone deacetylase inhibitors; medulloblastoma.

PubMed Disclaimer

References

    1. Algar E. M., Muscat A., Dagar V., Rickert C., Chow C. W., Biegel J. A., et al. (2009). Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 4:e4482. 10.1371/journal.pone.0004482 - DOI - PMC - PubMed
    1. Almeida V. R., Vieira I. A., Buendia M., Brunetto A. T., Gregianin L. J., Brunetto A. L., et al. (2017). Combined treatments with a retinoid receptor agonist and epigenetic modulators in human neuroblastoma cells. Mol. Neurobiol. 54 7610–7619. 10.1007/s12035-016-0250-3 - DOI - PubMed
    1. Anastas J. N., Zee B. M., Kalin J. H., Kim M., Guo R., Alexandrescu S., et al. (2019). Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36 528–544.e10. - PubMed
    1. Atlasi Y., Stunnenberg H. G. (2017). The interplay of epigenetic marks during stem cell differentiation and development. Nat. Rev. Genet. 18 643–658. 10.1038/nrg.2017.57 - DOI - PubMed
    1. Autin P., Blanquart C., Fradin D. (2019). Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancers 11:1530. 10.3390/cancers11101530 - DOI - PMC - PubMed